Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Korean Regulatory Post Marketing Surveillance for Somavert

NCTNCT05131100 (opens ClinicalTrials.gov in a new tab)Other idA6291047Other idNCT05131100
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
11 participants (actual)
Sponsor
Pfizer · Industry
Design
Not stated
Countries
1 country

South Korea

Start
13 Jul 2022
Primary completion
10 Nov 2025
Completion
10 Nov 2025
First posted
23 Nov 2021
Last update posted
23 Jul 2026
Conditions
Acromegaly

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20222023202420252026
  1. Ph –

    Korean Regulatory Post Marketing Surveillance for Somavert

    NCT05131100

    13 Jul 2022 to 10 Nov 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Interventions

  • SomavertDrug

Arms1

  • Other

    Participants receiving Somavert

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Number of participants who experience adverse events

    Time frame · Baseline through 28 days after last dose (approximately 52 weeks)

Secondary outcomes(1)

  1. Number of participants who experience Clinical Improvement as assessed by investigator

    Time frame · Baseline through approximately 52 weeks

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible. Exclusion Criteria: Patients who are contraindicated for Somavert

PepBank is a research reference. Talk to a doctor before you use any peptide.